Also known as Lucentis and Susvimo.
Approvals include Rasonque for metastatic pancreatic cancer, Foundayo oral GLP‑1 for weight and type 2 diabetes, Yuviwel for achondroplasia, two biosimilars and temozolomide for gliomas.
Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.
Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.
Continuous ranibizumab delivery via the Contivue refillable implant offers an alternative to monthly intravitreal injections, with as few as two treatments per year.
First continuous‑delivery ranibizumab implant for nAMD receives CHMP backing; designed to maintain vision with as few as two refills per year versus monthly injections.
ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.
Contivue with Susvimo offers continuous nAMD treatment, showing stable long-term vision outcomes with up to two refills yearly, backed by seven-year LADDER study data.
